![](/images/graphics-bg.png)
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant temozolomide
المؤلفون المشاركون
Yunus, Samar Jalal
Khidr, Rasha Abd al-Ghani
al-Sharbaji, Safinaz Hamid
المصدر
Journal of the Egyptian National Cancer Institute
العدد
المجلد 28، العدد 1 (31 مارس/آذار 2016)، ص ص. 23-30، 8ص.
الناشر
جامعة القاهرة المعهد القومي للأورام
تاريخ النشر
2016-03-31
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الموضوعات
الملخص EN
Background : O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ).
Methods : From April 2012 to October 2014, 73 patients with newly diagnosed GBM, MGMT protein expression were analyzed in formalin-fixed, paraffin-embedded tumor specimens.
Patients received the radiation therapy plus concomitant and adjuvant TMZ chemotherapy.
Results : For the whole cohort, the median overall survival (OS) was 15 months, and the progression-free survival was 10 months.
Patients who had low MGMT protein expression (615%) had a significantly improved OS and PFS compared with patients who had high MGMT expression (17.0 months vs 14 months; P value .006) and (15.0 months vs 10 months; P value .016) respectively.
The age and extent of tumor resection were the strongest clinical predictors of outcome.
In multivariate Cox models MGMT protein expression, extent of tumor resection and age were identified as independent prognostic factors.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Yunus, Samar Jalal& Khidr, Rasha Abd al-Ghani& al-Sharbaji, Safinaz Hamid. 2016. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant temozolomide. Journal of the Egyptian National Cancer Institute،Vol. 28, no. 1, pp.23-30.
https://search.emarefa.net/detail/BIM-667818
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Yunus, Samar Jalal…[et al.]. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant temozolomide. Journal of the Egyptian National Cancer Institute Vol. 28, no. 1 (Mar. 2016), pp.23-30.
https://search.emarefa.net/detail/BIM-667818
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Yunus, Samar Jalal& Khidr, Rasha Abd al-Ghani& al-Sharbaji, Safinaz Hamid. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant temozolomide. Journal of the Egyptian National Cancer Institute. 2016. Vol. 28, no. 1, pp.23-30.
https://search.emarefa.net/detail/BIM-667818
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 21-22
رقم السجل
BIM-667818
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)